Sigurður Guðmundsson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sigurður Guðmundsson has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Frank Espersen
Departments of Microbiology1 and Internal Medicine,4 Landspitalinn (University Hospital), Reykjavík, Iceland; Department of Infectious Diseases, University Hospital, Uppsala, Sweden3; and Statens Serum Institut, Copenhagen, Denmark2
1 shared publicationHelga Erlendsdottir
Departments of Microbiology, Landspitalinn (University Hospital), Reykjavík, Iceland
1 shared publicationInga Odenholt
Departments of Microbiology1 and Internal Medicine,4 Landspitalinn (University Hospital), Reykjavík, Iceland; Department of Infectious Diseases, University Hospital, Uppsala, Sweden3; and Statens Serum Institut, Copenhagen, Denmark2
1 shared publicationJenny Dahl Knudsen
Departments of Microbiology1 and Internal Medicine,4 Landspitalinn (University Hospital), Reykjavík, Iceland; Department of Infectious Diseases, University Hospital, Uppsala, Sweden3; and Statens Serum Institut, Copenhagen, Denmark2
1 shared publicationKarl G. Kristinsson
Departments of Microbiology1 and Internal Medicine,4 Landspitalinn (University Hospital), Reykjavík, Iceland; Department of Infectious Diseases, University Hospital, Uppsala, Sweden3; and Statens Serum Institut, Copenhagen, Denmark2
1 shared publicationKurt Fuursted
Departments of Microbiology1 and Internal Medicine,4 Landspitalinn (University Hospital), Reykjavík, Iceland; Department of Infectious Diseases, University Hospital, Uppsala, Sweden3; and Statens Serum Institut, Copenhagen, Denmark2
1 shared publication
Latest Publications
- 1 November 2004
- Vol. 90 (11) , 735-6
[Vioxx - What can we learn? [Editorial].].
- 1 March 2004
- Vol. 90 (3) , 203-4
[Disease prevention - curse or blessing? [Editorial].].
- 1 October 2002
- Vol. 88 (10) , 713-4
[Colorectal cancer screening [Editorial].].
- 1 January 2002
- Vol. 88 (1) , 7
[New year's thoughts on health care [Editorial].].
- Open Access
- 1 April 2001
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (4) , 1078-1085
Penicillin Pharmacodynamics in Four Experimental Pneumococcal Infection Models
Clinical and animal studies indicate that with optimal dosing, penicillin may still be effective against penicillin-nonsusceptible pneumococci (PNSP). The present study examined whether the same strains of penicillin-susceptible pneumococci (PSP) and PNSP differed in their pharmacodynamic responses to penicillin by using comparable penicillin dosing regimens in four animal models: peritonitis, pneumonia, and thigh infection in mice and tissue cage infection in rabbits. Two multidrug-resistant isolates of Streptococcus pneumoniae type 6B were used, one for which the penicillin MIC was 0.016 μg/ml and the other for which the penicillin MIC was 1.0 μg/ml. Two additional strains of PNSP were studied in the rabbit. The animals were treated with five different penicillin regimens resulting in different maximum concentrations of drugs in serum ( C max s) and times that the concentrations were greater than the MIC ( T >MIC s). The endpoints were bacterial viability counts after 6 h of treatment in the mice and 24 h of treatment in the rabbits. Similar pharmacodynamic effects were observed in all models. In the mouse models bactericidal activity depended on the T >MIC and to a lesser extent on the C max /MIC and the generation time but not on the area under the concentration-time curve (AUC)/MIC. Maximal bactericidal activities were similar for both PSP and PNSP, being the highest in the peritoneum and blood (∼6 log 10 CFU/ml), followed by the thigh (∼3 log 10 CFU/thigh), and being the lowest in the lung (∼1 log 10 CFU/lung). In the rabbit model the maximal effect was ∼6 log 10 CFU/ml after 24 h. In the mouse models bactericidal activity became marked when T >MIC was ≥65% of the experimental time and C max was ≥15 times the MIC, and in the rabbit model bactericidal activity became marked when T >MIC was ≥35%, C max was ≥5 times the MIC, and the AUC at 24 h/MIC exceeded 25. By optimization of the C max /MIC ratio and T >MIC , the MIC of penicillin for pneumococci can be used to guide therapy and maximize therapeutic efficacy in nonmeningeal infections caused by PNSP.
- 1 April 2001
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (4) , 1078-1085
Open AccessPenicillin Pharmacodynamics in Four Experimental Pneumococcal Infection Models
Clinical and animal studies indicate that with optimal dosing, penicillin may still be effective against penicillin-nonsusceptible pneumococci (PNSP). The present study examined whether the same strains of penicillin-susceptible pneumococci (PSP) and PNSP differed in their pharmacodynamic responses to penicillin by using comparable penicillin dosing regimens in four animal models: peritonitis, pneumonia, and thigh infection in mice and tissue cage infection in rabbits. Two multidrug-resistant isolates of Streptococcus pneumoniae type 6B were used, one for which the penicillin MIC was 0.016 μg/ml and the other for which the penicillin MIC was 1.0 μg/ml. Two additional strains of PNSP were studied in the rabbit. The animals were treated with five different penicillin regimens resulting in different maximum concentrations of drugs in serum ( C max s) and times that the concentrations were greater than the MIC ( T >MIC s). The endpoints were bacterial viability counts after 6 h of treatment in the mice and 24 h of treatment in the rabbits. Similar pharmacodynamic effects were observed in all models. In the mouse models bactericidal activity depended on the T >MIC and to a lesser extent on the C max /MIC and the generation time but not on the area under the concentration-time curve (AUC)/MIC. Maximal bactericidal activities were similar for both PSP and PNSP, being the highest in the peritoneum and blood (∼6 log 10 CFU/ml), followed by the thigh (∼3 log 10 CFU/thigh), and being the lowest in the lung (∼1 log 10 CFU/lung). In the rabbit model the maximal effect was ∼6 log 10 CFU/ml after 24 h. In the mouse models bactericidal activity became marked when T >MIC was ≥65% of the experimental time and C max was ≥15 times the MIC, and in the rabbit model bactericidal activity became marked when T >MIC was ≥35%, C max was ≥5 times the MIC, and the AUC at 24 h/MIC exceeded 25. By optimization of the C max /MIC ratio and T >MIC , the MIC of penicillin for pneumococci can be used to guide therapy and maximize therapeutic efficacy in nonmeningeal infections caused by PNSP.